Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review
Identifieur interne : 003491 ( Main/Exploration ); précédent : 003490; suivant : 003492Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review
Auteurs : Grant W. Cannon [États-Unis] ; Christopher G. Jackson [États-Unis] ; Cecil O. Samuelson Jr [États-Unis] ; John R. Ward [États-Unis] ; H. James Williams [États-Unis] ; Daniel O. Clegg [États-Unis]Source :
- Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 1985.
English descriptors
- Teeft :
- Alkylating, Arthritis, Arthritis rheum, Chlorambucil, Chlorambucil therapy, Chlorambucil toxicity, Clinical features, Clinical improvement, Clinical response, Cumulative dose, Cyclophosphamide, Cytotoxic, Daily dose, Dos, Drug toxicity, Hematocrit, Hematologic, Hematologic toxicity, Herpes, Herpes zoster, Histiocytosis, Leukemia, Leukopenia, Literature review, Malignancy, Malignant, Malignant histiocytosis, Osteoartic, Other saards, Platelet, Previous experience, Previous saard therapy, Previous treatment, Remission, Renier, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatol, Rhum, Saard, Saards, Significant differences, Therapy, Thrombocytopenia, Total dose, Toxicity.
Abstract
Abstract: Our clinical experience in 28 patients receiving chlorambucil for rheumatoid arthritis (RA) and the reports on chlorambucil therapy are reviewed. Our study population and other reports generally represent patients with severe RA who had either failed to improve or developed significant toxicity during previous treatment with conventional slow acting antirheumatic drugs (SAARDs). Seventy-two percent of patients had a significant clinical improvement during chlorambucil therapy and reports of complete remission are given, although the incidence of remission is unknown. Hematologic complications are often reported, but appeared more frequently in our experience than previously reported. Hematologic toxicity required that chlorambucil be discontinued in the majority of our cases. Two deaths from suspected drug induced malignancies are reported. Although chlorambucil appears to be effective in the control of active RA. the potential for drug induced toxicity and malignancies may outweigh the benefit of continued use of this experimental therapy in RA.
Url:
DOI: 10.1016/0049-0172(85)90028-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001640
- to stream Istex, to step Curation: 001640
- to stream Istex, to step Checkpoint: 002250
- to stream Main, to step Merge: 003565
- to stream Main, to step Curation: 003491
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review</title><author><name sortKey="Cannon, Grant W" sort="Cannon, Grant W" uniqKey="Cannon G" first="Grant W." last="Cannon">Grant W. Cannon</name></author><author><name sortKey="Jackson, Christopher G" sort="Jackson, Christopher G" uniqKey="Jackson C" first="Christopher G." last="Jackson">Christopher G. Jackson</name></author><author><name sortKey="Samuelson Jr, Cecil O" sort="Samuelson Jr, Cecil O" uniqKey="Samuelson Jr C" first="Cecil O." last="Samuelson Jr">Cecil O. Samuelson Jr</name></author><author><name sortKey="Ward, John R" sort="Ward, John R" uniqKey="Ward J" first="John R." last="Ward">John R. Ward</name></author><author><name sortKey="Williams, H James" sort="Williams, H James" uniqKey="Williams H" first="H. James" last="Williams">H. James Williams</name></author><author><name sortKey="Clegg, Daniel O" sort="Clegg, Daniel O" uniqKey="Clegg D" first="Daniel O." last="Clegg">Daniel O. Clegg</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:335908E57277A0F05EB9D57A4B34FB811639E046</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1016/0049-0172(85)90028-9</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-JGGNZ652-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001640</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001640</idno><idno type="wicri:Area/Istex/Curation">001640</idno><idno type="wicri:Area/Istex/Checkpoint">002250</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002250</idno><idno type="wicri:doubleKey">0049-0172:1985:Cannon G:chlorambucil:therapy:in</idno><idno type="wicri:Area/Main/Merge">003565</idno><idno type="wicri:Area/Main/Curation">003491</idno><idno type="wicri:Area/Main/Exploration">003491</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review</title><author><name sortKey="Cannon, Grant W" sort="Cannon, Grant W" uniqKey="Cannon G" first="Grant W." last="Cannon">Grant W. Cannon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Jackson, Christopher G" sort="Jackson, Christopher G" uniqKey="Jackson C" first="Christopher G." last="Jackson">Christopher G. Jackson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Samuelson Jr, Cecil O" sort="Samuelson Jr, Cecil O" uniqKey="Samuelson Jr C" first="Cecil O." last="Samuelson Jr">Cecil O. Samuelson Jr</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Ward, John R" sort="Ward, John R" uniqKey="Ward J" first="John R." last="Ward">John R. Ward</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Williams, H James" sort="Williams, H James" uniqKey="Williams H" first="H. James" last="Williams">H. James Williams</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author><author><name sortKey="Clegg, Daniel O" sort="Clegg, Daniel O" uniqKey="Clegg D" first="Daniel O." last="Clegg">Daniel O. Clegg</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Utah School of Medicine, Salt Lake City, Utah</wicri:regionArea><placeName><region type="state">Utah</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Seminars in Arthritis and Rheumatism</title><title level="j" type="abbrev">YSARH</title><idno type="ISSN">0049-0172</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1985">1985</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="106">106</biblScope><biblScope unit="page" to="118">118</biblScope></imprint><idno type="ISSN">0049-0172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0049-0172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alkylating</term><term>Arthritis</term><term>Arthritis rheum</term><term>Chlorambucil</term><term>Chlorambucil therapy</term><term>Chlorambucil toxicity</term><term>Clinical features</term><term>Clinical improvement</term><term>Clinical response</term><term>Cumulative dose</term><term>Cyclophosphamide</term><term>Cytotoxic</term><term>Daily dose</term><term>Dos</term><term>Drug toxicity</term><term>Hematocrit</term><term>Hematologic</term><term>Hematologic toxicity</term><term>Herpes</term><term>Herpes zoster</term><term>Histiocytosis</term><term>Leukemia</term><term>Leukopenia</term><term>Literature review</term><term>Malignancy</term><term>Malignant</term><term>Malignant histiocytosis</term><term>Osteoartic</term><term>Other saards</term><term>Platelet</term><term>Previous experience</term><term>Previous saard therapy</term><term>Previous treatment</term><term>Remission</term><term>Renier</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rhum</term><term>Saard</term><term>Saards</term><term>Significant differences</term><term>Therapy</term><term>Thrombocytopenia</term><term>Total dose</term><term>Toxicity</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Our clinical experience in 28 patients receiving chlorambucil for rheumatoid arthritis (RA) and the reports on chlorambucil therapy are reviewed. Our study population and other reports generally represent patients with severe RA who had either failed to improve or developed significant toxicity during previous treatment with conventional slow acting antirheumatic drugs (SAARDs). Seventy-two percent of patients had a significant clinical improvement during chlorambucil therapy and reports of complete remission are given, although the incidence of remission is unknown. Hematologic complications are often reported, but appeared more frequently in our experience than previously reported. Hematologic toxicity required that chlorambucil be discontinued in the majority of our cases. Two deaths from suspected drug induced malignancies are reported. Although chlorambucil appears to be effective in the control of active RA. the potential for drug induced toxicity and malignancies may outweigh the benefit of continued use of this experimental therapy in RA.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Utah</li></region></list><tree><country name="États-Unis"><region name="Utah"><name sortKey="Cannon, Grant W" sort="Cannon, Grant W" uniqKey="Cannon G" first="Grant W." last="Cannon">Grant W. Cannon</name></region><name sortKey="Clegg, Daniel O" sort="Clegg, Daniel O" uniqKey="Clegg D" first="Daniel O." last="Clegg">Daniel O. Clegg</name><name sortKey="Jackson, Christopher G" sort="Jackson, Christopher G" uniqKey="Jackson C" first="Christopher G." last="Jackson">Christopher G. Jackson</name><name sortKey="Samuelson Jr, Cecil O" sort="Samuelson Jr, Cecil O" uniqKey="Samuelson Jr C" first="Cecil O." last="Samuelson Jr">Cecil O. Samuelson Jr</name><name sortKey="Ward, John R" sort="Ward, John R" uniqKey="Ward J" first="John R." last="Ward">John R. Ward</name><name sortKey="Williams, H James" sort="Williams, H James" uniqKey="Williams H" first="H. James" last="Williams">H. James Williams</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003491 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003491 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:335908E57277A0F05EB9D57A4B34FB811639E046
|texte= Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review
}}
| This area was generated with Dilib version V0.6.33. |  |